Shares of Novo Nordisk (NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 (^GSPC 0.26%) gained 0.2%, and the Nasdaq Composite (^IXIC 0.02%) lost 0.1% on the day.
The pharmaceutical giant and maker of Ozempic and Wegovy reported better-than-expected numbers Wednesday morning. The drugmaker delivered 25% year-over-year (YOY) revenue growth, with 2024 sales coming in at $40.5 billion. That exceeded Wall Street's target of $39.5 billion. For Q4, the company reported $11.6 billion in sales -- up 30% YOY -- beating the expected $11.2 billion.
The strong performance was driven by the company's pair of semaglutide drugs, Wegovy and Ozempic. Of the full year's total sales of $40.5 billion, the two were responsible for $24.9 billion. Novo is leading the GLP-1 contest with 52% of the market share, outperforming key rivals like Eli Lilly.
However, as the company struggles to keep up with demand, it is taking on debt to bolster its manufacturing, which could eat into margins.
GLP-1 drugs like Ozempic require injections, severely limiting their adoption. While Novo Nordisk owns the market for now, a pill-based GLP-1 would be a game changer. The company is in a race with Eli Lilly to be first to market in the U.S. Whichever company does so could shift the balance of power significantly.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。